[China Chemical Instrument Network Famous Enterprise News] GE Healthcare provides a production platform based on bioprocess disposable technology, advanced processing automation and compact clean room structure, which can help customers quickly configure cGMP production capacity. Compared with traditional facilities, the one-time production platform greatly reduces the construction cost and cycle, helps accelerate the process of R&D drugs into clinical and commercial production, and improves the production capacity of partners and the ability to respond to risks.

On April 18, 2017, GE Healthcare and Sichuan Baili Tianheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Baili Pharmaceutical") held a signing ceremony in Chengdu to jointly announce the Chengdu Dote antibody drug under Baili Pharmaceutical Co., Ltd. (hereinafter referred to as "Dote Antibody") adopts the biopharmaceutical production line of GE Medical's disposable technology platform to build the first advanced antibody drug production base in Chengdu that meets the GMP standards of China, the United States and Europe, and it is completed and put into production.

Dot Antibody is based on GE's single-use technology biopharmaceutical production line, based on the production of innovative monoclonal antibodies, multispecific antibodies, and antibody conjugate drugs (ADC). Dot Antibody will become the first antibody drug to settle in the Chengdu Medical City Industrial Park. Pharmaceutical companies. The innovative development of Baili Pharmaceutical's antibody drugs will drive the introduction of high-end talents and advanced projects in the industrial park, as well as the formation of the antibody drug industry chain, thereby promoting the upgrading of the biopharmaceutical industry in Chengdu and even the southwestern region. In recent years, China has vigorously supported the development of the biomedical industry. As one of the seven emerging strategic industries in China, the biopharmaceutical industry has become the focus of China's high-tech development. In Chengdu, the biopharmaceutical industry ranks at the forefront of the list of key development industries. Zhu Yi, Chairman of Sichuan Baili Tianheng Pharmaceutical Co., Ltd., said: "'Let patients gain health and vitality" has always been one of Baili's core values.

For a long time, we have built a diversified and leading research product line in the field of tumor antibody drugs through a strong sustainable and innovative R&D platform and Chinese and foreign R&D teams. With the help of GE Healthcare's flexible biopharmaceutical production platform based on bioprocess disposable technology, we will build a domestic first-class biopharmaceutical production base, and accelerate to bring higher quality and more affordable innovative antibodies to patients with higher production capacity. With abundant services and technology exports, it will drive the overall development of biopharmaceuticals in industrial parks and even in the southwestern region. "The production platform based on bioprocess disposable technology, advanced processing automation and compact clean room structure provided by GE Healthcare can help customers quickly configure cGMP production capacity. Compared with traditional facilities, the disposable production platform greatly reduces construction costs and The cycle helps to accelerate the process of R&D drugs entering clinical and commercial production, and improve the production capacity of partners and the ability to respond to risks. During the construction period, GE Healthcare strictly follows the cGMP guidelines and actively contributes to workshop construction, equipment manufacturing, installation and commissioning, and personnel Training, etc., provided full technical support and services. Mr. Li Qing, general manager of GE Healthcare's Life Sciences Division, said: “GE Healthcare and Bailey Pharmaceuticals are both companies focusing on'innovation'. As a long-term partner of Chinese biopharmaceutical companies, we are always assisting the R&D and production of biopharmaceutical companies with innovative technologies and solutions, while Bailey Pharmaceuticals drives the continuous advancement of companies and industries through innovative drug research and development. The cooperation between the two parties will fully bring together the power of ‘innovation’ to accelerate innovation and allow more patients to benefit from it. "

It is reported that the innovative tumor antibody drug production base of Dote Antibody based on GE's single-use technology platform officially started construction in October 2016 and was put into operation on April 18, 2017.

Editor's comment

Nowadays, GE Healthcare has participated in the continuous development of biopharmaceutical production lines. With the help of biotechnology, GE Healthcare has formed a biopharmaceutical industry chain development model. In the future, it will continue to inject its own R&D technologies in clinical medicine, biomedicine, antibody drugs, etc. .

(Original title: GE Healthcare's "disposable technology" boosts the upgrading of the biopharmaceutical industry in Southwest China) (Source: GE Healthcare)